



**University of Dundee**

**Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels**

Tin, Adrienne; Marten, Jonathan; Halperin Kuhns, Victoria L.; Li, Yong; Wuttke, Matthias

*Published in:*  
Nature Genetics

*DOI:*  
[10.1038/s41588-019-0504-x](https://doi.org/10.1038/s41588-019-0504-x)

*Publication date:*  
2019

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*

, Tin, A., Marten, J., Halperin Kuhns, V. L., Li, Y., Wuttke, M., Kirsten, H., Sieber, K. B., Qiu, C., Gorski, M., Yu, Z., Giri, A., Sveinbjornsson, G., Li, M., Chu, A. Y., Hoppmann, A., O'Connor, L. J., Prins, B., Nutile, T., ... Kottgen, A. (2019). Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. *Nature Genetics*, 51(10), 1459–1474 . <https://doi.org/10.1038/s41588-019-0504-x>

**General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

**Target genes, variants, tissues and transcriptional pathways for the regulation of serum urate levels in humans**

Adrienne Tin, Jonathan Marten, Victoria Halperin Kuhns,  
Yong Li, Matthias Wuttke, Holger Kirsten, *et al.*

SUPPLEMENTARY INFORMATION

## Table of Contents

<b>SUPPLEMENTARY NOTE 1: EXTENDED ACKNOWLEDGEMENTS .....</b>	<b>3</b>
--	----------

## **Supplementary Note 1: Extended Acknowledgements**

The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. Variant annotation was supported by software resources provided via the Caché Campus program of the InterSystems GmbH to Alexander Teumer.

### ***Study-specific acknowledgements and funding sources***

- AGES** This study has been funded by NIA contract N01-AG-12100 and HHSN271201200022C with contributions from NEI, NIDCD and NHLBI, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics Committee, VSN: 00-063. The researchers are indebted to the participants for their willingness to participate in the study.
- Amish** We thank our Amish research volunteers for their long-standing partnership in research, and the research staff at the Amish Research Clinic for their hard work and dedication. The Amish contribution was supported by NIH grants R01 AG18728, R01 HL088119, U01 GM074518, U01 HL072515, U01 HL084756, and NIH K12RR023250, and P30 DK072488. Additional support was provided by the University of Maryland General Clinical Research Center, grant M01 RR 16500, the Baltimore Veterans Administration Medical Center Geriatrics Research, and the Paul Beeson Physician Faculty Scholars in Aging Program.
- ARIC** The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. The work of AK was supported by a Heisenberg Professorship (KO 3598/3-1, 3598/5-1) as well as CRC 1140 project number 246781735 and CRC 992 of the German Research Foundation. Adriennne Tin is supported by NIAMS grant R01AR073178-01A1.
- ASPS, ASPS-Fam** The authors thank the staff and the participants for their valuable contributions. We thank Birgit Reinhart for her long-term administrative commitment, Elfi Hofer for the technical assistance at creating the DNA bank, Ing. Johann Semmler and Anita Harb for DNA sequencing and DNA analyses by TaqMan assays and Irmgard Poelzl for supervising the quality management processes after ISO9001 at the biobanking and DNA analyses. The research reported in this article was funded by the Austrian Science Fond (FWF) grant number

P20545-P05, P13180 and PI904 as well as by the Austrian National Bank (OeNB) Anniversary Fund grant number P15435 and the Austrian Federal Ministry of Science, Research and Economy under the aegis of the EU Joint Programme-Neurodegenerative Disease Research (JPND)-www.jpnd.eu. The Medical University of Graz supports the databank of the ASPS.

**BBJ** The BioBank Japan project is supported by the Ministry of Education, Culture, Sports, Sciences and Technology of Japanese government and the Japan Agency for Medical Research and Development.

**BioMe** The Mount Sinai IPM Biobank Program is supported by The Andrea and Charles Bronfman Philanthropies. Ruth loos is funded by R01DK110113, U01HG007417, R01DK101855, R01DK107786.

**CHNS** The China Health and Nutrition Survey (CHNS) was supported by the China National Institute of Nutrition and Food Safety; the China Center for Disease Control; the National Institutes of Health (R01HD30880, R01HL108427, and R01DK104371); the Fogarty International Center of the National Institutes of Health; the China-Japan Friendship Hospital; the Chinese Ministry of Health; and the Carolina Population Center (R24 HD050924). Cassandra N. Spracklen was supported by the American Heart Association Postdoctoral Fellowship (17POST3650016).

**CHRIS** Full acknowledgements for the CHRIS study are reported here: <http://translational-medicine.biomedcentral.com/articles/10.1186/s12967-015-0704-9#Declarations>. The CHRIS study was funded by the Department of Innovation, Research, and University of the Autonomous Province of Bolzano-South Tyrol.

**CHS** This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, R01HL085251, and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org.

The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Cilento** We thank the populations of Cilento for their participation in the study. This work was supported by grants from the Italian Ministry of Universities and Research and CNR (Interomics Flagship Project,

PON03PE\_00060\_7), the Assessorato Ricerca Regione Campania, the Fondazione con il SUD (2011-PDR-13), and the Istituto Banco di Napoli - Fondazione to MC.

**CoLaus**

The CoLaus|PsyCoLaus study was and is supported by research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (grants 3200B0-105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468 and 33CS30-148401).

**CROATIA-Korcula,  
CROATIA-Split,  
CROATIA-Vis**

10001 Dalmatians: The Croatian Biobank (CROATIA) The CROATIA-Vis, CROATIA-Korcula and CROATIA-Split were funded by grants from the Medical Research Council (UK), from the Republic of Croatia Ministry of Science, Education and Sports (108-1080315-0302; 216-1080315-0302) and the Croatian Science Foundation (8875); and the CROATIA-Korčula genotyping was funded by the European Union framework program 6 project EUROSPAN (LSHGCT2006018947). We would like to acknowledge the staff of several institutions in Croatia that supported the field work, including Zagreb Medical Schools, the Institute for Anthropological Research in Zagreb, the recruitment team from the Croatian Centre for Global Health, University of Split and all the study participants. We are grateful to the Helmholtz Zentrum Munchen (Munich, Germany), AROS Applied Biotechnology, (Aarhus, Denmark) and the Edinburgh Clinical Research facility, University of Edinburgh (Edinburgh, United Kingdom) for SNP array genotyping. Genetic analyses were supported by the MRC HGU “QTL in Health and Disease” core programme.

**CZECH POST-MONICA**

The study was supported by research grant 15-27109A provided by the Health Research Agency of the Ministry of Health, Czech Republic; Krka, tovarna zdravil, d.d., Novo mesto, Slovenia; Servier s.r.o., Czech Republic.

**DECODE**

The study was funded by deCODE Genetics/Amgen inc. We thank the study subjects for their valuable participation and our colleagues, who contributed to data collection, sample handling, and genotyping.

**DIACORE**

Cohort recruiting and management was funded by the KfH Stiftung Präventivmedizin e.V. (CAB). Genome-wide genotyping was funded the Else Kröner-Fresenius-Stiftung (2012\_A147), the KfH Stiftung Präventivmedizin and the University Hospital Regensburg. Data analysis was funded by the Else Kröner-Fresenius Stiftung (2012\_A147) and by the Deutsche Forschungsgemeinschaft with grant DFG BO 3815/1-4.

**EGCUT**

The EGCUT studies were financed by Estonian Government (grants IUT20-60 and IUT24-6) and by European Commission through the European Regional Development Fund in the frame of grant Estonian Center of Genomics/Roadmap II (project No. 2014-2020.4.01.16-0125) and grant GENTRANSMED (Project No. 2014-2020.4.01.15-0012) and through H2020 grant no 692145 (ePerMed).

**ERF**

The Erasmus Rucphen Family (ERF) has received funding from the Centre for Medical Systems Biology (CMSB) and Netherlands Consortium for Systems Biology (NCSB), both within the framework of the Netherlands Genomics Initiative (NGI)/Netherlands Organization

for Scientific Research (NWO). ERF study is also a part of EUROSPAN (European Special Populations Research Network) (FP6 STRP grant number 018947 (LSHG-CT-2006-01947)); European Network of Genomic and Genetic Epidemiology (ENGAGE) from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413; "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no. QL2-CT-2002-01254); FP7 project EUROHEADPAIN (nr 602633), the Internationale Stichting Alzheimer Onderzoek (ISAO); the Hersenstichting Nederland (HSN); and the JNPD under the project PERADES (grant number 733051021, Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease using multiple powerful cohorts, focused Epigenetics and Stem cell metabolomics). We are grateful to all study participants and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, J. Vergeer for the supervision of the laboratory work, and P. Snijders M.D. for his help in data collection of the data. J.L., C.M.v.D., and A.D. have used exchange grants from the Personalized pREvention of Chronic Diseases consortium (PRECeDI). A.D. is supported by a Veni grant (2015) from ZonMw.

**FHS**

The Framingham Heart Study is supported by HHSN268201500001.

**FINCAVAS**

The Finnish Cardiovascular Study (FINCAVAS) has been financially supported by the Competitive Research Funding of the Tampere University Hospital (Grant 9M048 and 9N035), the Finnish Cultural Foundation, the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, Finland, the Tampere Tuberculosis Foundation, and EU Horizon 2020 (grant 755320 for TAXINOMISIS). The authors thank the staff of the Department of Clinical Physiology for collecting the exercise test data.

**GCKD**

The GCKD study was funded by the German Ministry of Research and Education (Bundesministerium für Bildung und Forschung, BMBF) and by the Foundation KfH Stiftung Präventivmedizin. Unregistered grants to support the study were provided by Bayer, Fresenius Medical Care and Amgen. Genotyping was supported by Bayer Pharma AG. The work of MW was supported by DFG CRC 1140 project number 246781735 and the Else Kroener Fresenius Forschungskolleg NAKSYS. The work of YL was supported by DFG KO 3598/4-1. The work of AH was partly supported by NIDDK R01 DK087635-09.

**GS:SFHS**

Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. We are grateful to all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland and was funded by the Medical

Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award “STratifying Resilience and Depression Longitudinally” (STRADL) Reference 104036/Z/14/Z).

**GSK**

Funding Source: Max-Planck Society, German Federal Ministry of Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN), Foerderkennzeichen 01GS0481.

**HANDLS**

The authors would thank all study participants and the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study medical staff for their contributions. The HANDLS study was supported by the Intramural Research Program of the NIH, National Institute on Aging and the National Center on Minority Health and Health Disparities (project # Z01-AG000513 and human subjects protocol number 09-AG-N248). Data analyses for the HANDLS study utilized the high-performance computational resources of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD. (<http://biowulf.nih.gov>; <http://hpc.nih.gov>).

**HYPERGENES**

HYPERGENES project (FP7-HEALTH-F4-2007-201550) and InterOmics (PB05 MIUR-CNR Italian Flagship Project).

**INGI-CARL**

The project was approved by the local administration of Carlantino, the Health Service of Foggia Province, Italy, and ethical committee of the IRCCS Burlo-Garofolo of Trieste. We would like to thank the people of the Friuli Venezia Giulia Region and of Carlantino for the everlasting support.

**INGI-FVG**

Project co-financed by the European Regional Development Fund under the Regional Operational Programme of Friuli Venezia Giulia - Objective "Regional Competitiveness and Employment" 2007/2013, Telethon Foundation (GGP09037), Fondo Trieste (2008), Regione FVG (L.26.2008), and Italian Ministry of Health (RC16/06, ART. 13 D.LGS 297/99) (to PG). We would like to thank the people of the Friuli Venezia Giulia Region and of Carlantino for the everlasting support.

**INGI-VBI**

The research was supported by funds from Compagnia di San Paolo, Torino, Italy; Fondazione Cariplo, Italy and Ministry of Health, Ricerca Finalizzata 2011 and CCM 2010 to DT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank the inhabitants of the VB that made this study possible, the local administrations, the Tortona and Genova archdiocese and the ASL-22, Novi Ligure (AI) for support. We also thank Clara Camaschella for data collection supervision and organization of the clinical data collection, Fiammetta Viganò for technical help, Corrado Masciullo and Massimiliano Cocca for building the analysis platform.

**JHS**

The Jackson Heart Study (JHS) is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I/HHSN26800001) and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I and HHSN268201800012I) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute for Minority Health and Health Disparities (NIMHD). The



authors also wish to thank the staffs and participants of the JHS. James G. Wilson is supported by U54GM115428 from the National Institute of General Medical Sciences. Laura M. Raffield is supported by T32 HL129982.

#### **KORA**

The KORA research platform (KORA, Cooperative Health Research in the Region of Augsburg) was initiated and financed by the Helmholtz Zentrum München - German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. Data analysis was funded by the Else Kröner-Fresenius Stiftung (2012\_A147) and by the Deutsche Forschungsgemeinschaft with grant DFG BO 3815/1-4.

#### **LIFE-Adult, LIFE-Heart, LIFE-Child**

LIFE-Adult, LIFE-Heart and LIFE-Child are funded by the Leipzig Research Center for Civilization Diseases (LIFE). LIFE is an organizational unit affiliated to the Medical Faculty of the University of Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by funds of the Free State of Saxony within the framework of the excellence initiative.

#### **Lifelines**

The Lifelines Cohort Study, and generation and management of GWAS genotype data for the Lifelines Cohort Study is supported by the Netherlands Organization of Scientific Research NWO (grant 175.010.2007.006), the Economic Structure Enhancing Fund (FES) of the Dutch government, the Ministry of Economic Affairs, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern Netherlands Collaboration of Provinces (SNN), the Province of Groningen, University Medical Center Groningen, the University of Groningen, Dutch Kidney Foundation and Dutch Diabetes Research Foundation. The authors wish to acknowledge the services of the Lifelines Cohort Study, the contributing research centers delivering data to Lifelines, and all the study participants.

#### **LOLIPOP**

The LOLIPOP study is supported by the National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre Imperial College Healthcare NHS Trust, the British Heart Foundation (SP/04/002), the Medical Research Council (G0601966, G0700931), the Wellcome Trust (084723/Z/08/Z, 090532 & 098381) the NIHR (RP-PG-0407-10371), the NIHR Official Development Assistance (ODA, award 16/136/68), the European Union FP7 (EpiMigrant, 279143) and H2020 programs (iHealth-T2D, 643774). We acknowledge support of the MRC-PHE Centre for Environment and Health, and the NIHR Health Protection Research Unit on Health Impact of Environmental Hazards. The work was carried out in part at the NIHR/Wellcome Trust Imperial Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the Imperial College Healthcare NHS Trust, the NHS, the NIHR or the Department of Health. We thank the participants and research staff who made the study possible. JC is supported by the Singapore Ministry of Health's National Medical Research Council under its Singapore Translational Research Investigator (STaR) Award

(NMRC/STaR/0028/2017).

**LURIC**

LURIC was supported by the 7th Framework Program of the EU (AtheroRemo, grant agreement number 201668 and RiskyCAD, grant agreement number 305739). The work of W.M. and M.E.K. is supported as part of the Competence Cluster of Nutrition and Cardiovascular Health (nutriCARD) which is funded by the German Ministry of Education and Research (grant agreement number 01EA1411A). The authors thank the LURIC study team who were involved in patient recruitment as well as sample and data handling, in addition to the laboratory staff at the Ludwigshafen General Hospital and the universities of Freiburg, Ulm and Heidelberg, Germany.

**MICROS**

We owe a debt of gratitude to all participants, all primary care practitioners, and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project. The study was supported by the Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano, the South Tyrolean Sparkasse Foundation, and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947).

**MVP**

This work was supported by the MVP-VA Award #I01BX003360 (PI A.M.H), and Adriana M. Hung (A.M.H) was supported by VA Award #I01BX003360. Additional MVP acknowledgements are included at the end of this section.

**MyCode  
(Geisinger)**

We acknowledge the participants, staff, and our colleagues associated with the Geisinger MyCode Community Health Initiative. We also thank the staff of the PACDC of Geisinger for assistance with the phenotypic data, and the staff of the Biomedical & Translational Informatics and Kidney Health Research Institute.

**NEO**

The authors of the NEO study thank all individuals who participated in the Netherlands Epidemiology in Obesity study, all participating general practitioners for inviting eligible participants and all research nurses for collection of the data. We thank the NEO study group, Pat van Beelen, Petra Noordijk and Ingeborg de Jonge for the coordination, lab and data management of the NEO study. The genotyping in the NEO study was supported by the Centre National de Génotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO study is supported by the participating Departments, the Division and the Board of Directors of the Leiden University Medical Center, and by the Leiden University, Research Profile Area Vascular and Regenerative Medicine. Dennis Mook-Kanamori is supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023).

**NESDA**

Funding was obtained from the Netherlands Organization for Scientific Research (Geestkracht program grant 10-000-1002); the Center for Medical Systems Biology (CSMB, NWO Genomics), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL), VU University's Institutes for Health and Care Research (EMGO+) and Neuroscience Campus Amsterdam, University Medical Center Groningen, Leiden University Medical Center, National Institutes of Health (NIH, R01D0042157-01A, MH081802, Grand

Opportunity grants 1RC2 MH089951 and 1RC2 MH089995). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. Computing was supported by BiG Grid, the Dutch e-Science Grid, which is financially supported by NWO.

**OGP** The study was supported by grant from the Italian Ministry of Education, University and Research (MIUR) n°: 5571/DSPAR/2002. We express our gratitude to all the study participants for their contributions and to the municipal administrations for their economic and logistic support.

**ORCADES** The Orkney Complex Disease Study (ORCADES) was supported by the Chief Scientist Office of the Scottish Government (CZB/4/276, CZB/4/710), a Royal Society URF to J.F.W., the MRC Human Genetics Unit quinquennial programme “QTL in Health and Disease”, Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947). DNA extractions were performed at the Wellcome Trust Clinical Research Facility in Edinburgh.

**PREVEND** The Prevention of Renal and Vascular Endstage Disease Study (PREVEND) genetics is supported by the Dutch Kidney Foundation (Grant E033), the EU project grant GENECURE (FP-6 LSHM CT 2006 037697), the National Institutes of Health (grant LM010098), the Netherlands organisation for health research and development (NWO VENI grant 916.761.70), and the Dutch Inter University Cardiology Institute Netherlands (ICIN). Niek Verweij was supported by NWO VENI grant 016.186.125.

**QIMR adolescent** We acknowledge funding by Australian National Health and Medical Research Council (NHMRC) grants 241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485, 552498 and Australian Research Council grants A7960034, A79906588, A79801419, DP0770096, DP0212016, DP0343921 for building and maintaining the adolescent twin family resource through which samples were collected.

**QIMR adult** We acknowledge the contributions of many staff in the Genetic Epidemiology Unit, Queensland Institute of Medical Research, in interviewing study participants, sample processing and DNA extraction, and data management. Funding for aspects of this work was provided by the Australian National Health and Medical Research Council (241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485, 552498), the Australian Research Council (A7960034, A79906588, A79801419, DP0770096, DP0212016, DP0343921), the EU 5th Framework Programme GenomEUtwin Project (QLG2-CT-2002-01254), and the U.S. National Institutes of Health (AA07535, AA10248, AA11998, AA13320, AA13321, AA13326, AA14041, AA17688, DA12854, MH66206 ). G.W.M. was supported by National Health and Medical Research Council (NHMRC) Fellowship Schemes.

**RS** The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population

Screening Act WBO, license number 1071272-159521-PG). The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; [www.trialregister.nl](http://www.trialregister.nl)) and into the WHO International Clinical Trials Registry Platform (ICTRP; [www.who.int/ictrp/network/primary/en/](http://www.who.int/ictrp/network/primary/en/)) under shared catalogue number NTR6831. All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians. The generation and management of GWAS genotype data for the Rotterdam Study (RS I, RS II, RS III) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, MSc, and Carolina Medina-Gomez, MSc, for their help in creating the GWAS database, and Karol Estrada, PhD, Yurii Aulchenko, PhD, and Carolina Medina-Gomez, MSc, for the creation and analysis of imputed data. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists.

**SHIP/SHIP-Trend**

SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network 'Greifswald Approach to Individualized Medicine (GANI\_MED)' funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg- West Pomerania. The University of Greifswald is a member of the Caché Campus program of the InterSystems GmbH. Variant annotation was supported by software resources provided via the Caché Campus program of the InterSystems GmbH to Alexander Teumer.

**SKIPOGH**

The SKIPOGH study is supported by a grant from the Swiss national science foundation (FN33CM30-124087).

**Sorbs**

This work was supported by grants from the German Research Foundation (Project number 209933838; SFB-1052 "Obesity

mechanisms” A01, B03, SPP 1629 TO 718/2- 1), from the German Diabetes Association, from the DHFD (Diabetes Hilfs- und Forschungsfonds Deutschland) and from IFB Adiposity Diseases (AD2-060E, AD2-06E95, AD2-06E99). IFB Adiposity Diseases is supported by the Federal Ministry of Education and Research (BMBF), Germany (FKZ: 01EO1501)

**UKBB** This research has been conducted using the UK Biobank Resource under Application Numbers 20272, 7439 and 19655.

**ULSAM** JÄ was supported by The Swedish Research Council, Swedish Heart-Lung Foundation, Dalarna University and Uppsala University. The ULSAM study was supported by Wellcome Trust grants WT098017, WT064890, WT090532, Uppsala University, Uppsala University Hospital, the Swedish Research Council and the Swedish Heart-Lung Foundation.

**Vanderbilt** The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center’s BioVU which is supported by numerous sources: institutional funding, private agencies, and federal grants. These include the NIH funded Shared Instrumentation Grant S10RR025141; and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at <https://victr.vanderbilt.edu/pub/biovu/>.

**VIKING** The Viking Health Study – Shetland (VIKING) was supported by the MRC Human Genetics Unit quinquennial programme grant “QTL in Health and Disease”. DNA extractions and genotyping were performed at the Edinburgh Clinical Research Facility, University of Edinburgh. We would like to acknowledge the invaluable contributions of the research nurses in Shetland, the administrative team in Edinburgh and the people of Shetland.

**YFS** The Young Finns Study has been financially supported by the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research ; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; and EU Horizon 2020 (grant 755320 for TAXINOMISIS); and European Research Council (grant 742927 for MULTIEPIGEN project). We thank the teams that collected data at all measurement time points; the persons who participated as both children and adults in these longitudinal studies; and biostatisticians Irina Lisinen, Johanna Ikonen, Noora Kartiosuo, Ville Aalto, and Jarno Kankaanranta for data management and statistical advice.

**Experimental** Functional experiments in the Woodward laboratory were supported

**study**

by grants from the NIDDK: (A) R01DK114091, and (B) the Baltimore PKD Research and Clinical Core Center 5P30DK090868. We also want to thank Douglas D. Ross of the University of Maryland for the generous gift of the *ABCG2* promoter luciferase construct.

**LifeLines Cohort Study – Author Group**

Behrooz Z Alizadeh (1), H Marika Boezen (1), Lude Franke (2), Pim van der Harst (3), Gerjan Navis (4), Marianne Rots (5), Morris Swertz (2), Bruce HR Wolffenbuttel (6), Cisca Wijmenga (2)

(1) Department of Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands

(2) Department of Genetics, University of Groningen, University Medical Center Groningen, The Netherlands

(3) Department of Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands

(4) Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, The Netherlands

(5) Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, The Netherlands

(6) Department of Endocrinology, University of Groningen, University Medical Center Groningen, The Netherlands

**Million Veteran Program: Consortium Acknowledgement****MVP Executive Committee**

- Co-Chair: J. Michael Gaziano, M.D., M.P.H.
- Co-Chair: Rachel Ramoni, D.M.D., Sc.D.
- Jim Breeling, M.D. (ex-officio)
- Kyong-Mi Chang, M.D.
- Grant Huang, Ph.D.
- Sumitra Muralidhar, Ph.D.
- Christopher J. O'Donnell, M.D., M.P.H.
- Philip S. Tsao, Ph.D.

**MVP Program Office**

- Sumitra Muralidhar, Ph.D.
- Jennifer Moser, Ph.D.

**MVP Recruitment/Enrollment**

- Recruitment/Enrollment Director/Deputy Director, Boston – Stacey B. Whitbourne, Ph.D.; Jessica V. Brewer, M.P.H.
- MVP Coordinating Centers
  - o Clinical Epidemiology Research Center (CERC), West Haven – John Concato, M.D., M.P.H.
  - o Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque - Stuart Warren, J.D., Pharm D.; Dean P. Argyres, M.S.
  - o Genomics Coordinating Center, Palo Alto – Philip S. Tsao, Ph.D.
  - o Massachusetts Veterans Epidemiology Research Information Center (MAVERIC), Boston - J. Michael Gaziano, M.D., M.P.H.
  - o MVP Information Center, Canandaigua – Brady Stephens, M.S.

- Core Biorepository, Boston – Mary T. Brophy M.D., M.P.H.; Donald E. Humphries, Ph.D.
- MVP Informatics, Boston – Nhan Do, M.D.; Shahpoor Shayan
- Data Operations/Analytics, Boston – Xuan-Mai T. Nguyen, Ph.D.

### **MVP Science**

- Genomics - Christopher J. O'Donnell, M.D., M.P.H.; Saiju Pyarajan Ph.D.; Philip S. Tsao, Ph.D.
- Phenomics - Kelly Cho, M.P.H, Ph.D.
- Data and Computational Sciences – Saiju Pyarajan, Ph.D.
- Statistical Genetics – Elizabeth Hauser, Ph.D.; Yan Sun, Ph.D.; Hongyu Zhao, Ph.D.

### **MVP Local Site Investigators**

- Atlanta VA Medical Center (Peter Wilson)
  - Bay Pines VA Healthcare System (Rachel McArdle)
  - Birmingham VA Medical Center (Louis Dellitalia)
  - Cincinnati VA Medical Center (John Harley)
  - Clement J. Zablocki VA Medical Center (Jeffrey Whittle)
  - Durham VA Medical Center (Jean Beckham)
  - Edith Nourse Rogers Memorial Veterans Hospital (John Wells)
  - Edward Hines, Jr. VA Medical Center (Salvador Gutierrez)
  - Fayetteville VA Medical Center (Gretchen Gibson)
  - VA Health Care Upstate New York (Laurence Kaminsky)
  - New Mexico VA Health Care System (Gerardo Villareal)
  - VA Boston Healthcare System (Scott Kinlay)
  - VA Western New York Healthcare System (Junzhe Xu)
  - Ralph H. Johnson VA Medical Center (Mark Hamner)
  - Wm. Jennings Bryan Dorn VA Medical Center (Kathlyn Sue Haddock)
  - VA North Texas Health Care System (Sujata Bhushan)
  - Hampton VA Medical Center (Pran Iruvanti)
  - Hunter Holmes McGuire VA Medical Center (Michael Godschalk)
  - Iowa City VA Health Care System (Zuhair Ballas)
  - Jack C. Montgomery VA Medical Center (Malcolm Buford)
  - James A. Haley Veterans' Hospital (Stephen Mastorides)
  - Louisville VA Medical Center (Jon Klein)
  - Manchester VA Medical Center (Nora Ratcliffe)
  - Miami VA Health Care System (Hermes Florez)
  - Michael E. DeBakey VA Medical Center (Alan Swann)
  - Minneapolis VA Health Care System (Maureen Murdoch)
  - N. FL/S. GA Veterans Health System (Peruvemba Sriram)
  - Northport VA Medical Center (Shing Shing Yeh)
  - Overton Brooks VA Medical Center (Ronald Washburn)
  - Philadelphia VA Medical Center (Darshana Jhala)
  - Phoenix VA Health Care System (Samuel Aguayo)
  - Portland VA Medical Center (David Cohen)
  - Providence VA Medical Center (Satish Sharma)
  - Richard Roudebush VA Medical Center (John Callaghan)
  - Salem VA Medical Center (Kris Ann Oursler)
  - San Francisco VA Health Care System (Mary Whooley)
  - South Texas Veterans Health Care System (Sunil Ahuja)
  - Southeast Louisiana Veterans Health Care System (Amparo Gutierrez)
- Current as of 19-JUL-2018
- Southern Arizona VA Health Care System (Ronald Schifman)
  - Sioux Falls VA Health Care System (Jennifer Greco)

- St. Louis VA Health Care System (Michael Rauchman)
- Syracuse VA Medical Center (Richard Servatius)
- VA Eastern Kansas Health Care System (Mary Oehlert)
- VA Greater Los Angeles Health Care System (Agnes Wallbom)
- VA Loma Linda Healthcare System (Ronald Fernando)
- VA Long Beach Healthcare System (Timothy Morgan)
- VA Maine Healthcare System (Todd Stapley)
- VA New York Harbor Healthcare System (Scott Sherman)
- VA Pacific Islands Health Care System (Gwenevere Anderson)
- VA Palo Alto Health Care System (Philip Tsao)
- VA Pittsburgh Health Care System (Elif Sonel)
- VA Puget Sound Health Care System (Edward Boyko)
- VA Salt Lake City Health Care System (Laurence Meyer)
- VA San Diego Healthcare System (Samir Gupta)
- VA Southern Nevada Healthcare System (Joseph Fayad)
- VA Tennessee Valley Healthcare System (Adriana Hung)
- Washington DC VA Medical Center (Jack Lichy)
- W.G. (Bill) Hefner VA Medical Center (Robin Hurley)
- White River Junction VA Medical Center (Brooks Robey)
- William S. Middleton Memorial Veterans Hospital (Robert Striker)